Ankaferd Blood Stopper for Hemostasis After Transradial Coronary Angiography

Acibadem University600 enrolled

Overview

In 2008 Goker et al, introduced Ankaferd Blood Stopper (ABS) as a new hemostatic drug. Recently, ABS has been shown to produce local hemostasis by implementing topically after major arterial vessel injury. Reducing the compression time during patent hemostasis by facilitating hemostasis may decrease RAO. To test this hypothesis the investigators planned a three arm randomized study to evaluate the safety and efficacy of Ankaferd blood stopper in adjunct to short-time compression, compared to either short-time compression with conventional sterile gauzes or with a TR band after transradial diagnostic procedures.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

600

Conditions

Radial Artery Injury Hematoma Bleed

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All consecutive patients undergoing transradial elective diagnostic coronary procedures between November 2016 and November 2017 at the catheterization laboratory of Acibadem University Kocaeli Hospital were considered to be enrolled in the study. Exclusion Criteria: * The only exclusion criteria were an abnormal Barbeau's test before puncture and failure to provide written informed consent.

Outcomes

Primary Outcomes

Radial artery occlusion assessed by reverse Barbeau's test

Time frame: 24 hours

Secondary Outcomes

Bleeding

any kind of bleeding defined as ml after the removal of hemostatic dressings or devices

Time frame: 2 hours

Hematoma

hematomas larger then \>5cm